Preclinical studies have demonstrated the therapeutic efficacy of both mGluR3 and mGluR5 agonists in schizophrenia, including the improvement of negative symptoms and cognitive deficits that are often unresponsive to current antipsychotics [44, 45]. The gene discussed is GRM5; the disease is Cognitive impairment.